Leap Therapeutics Says Net Proceeds From April 2024 $37.2M Financing, Combined With Existing Cash, Cash Equivalents And Marketable Securities Of $54.9M, Are Expected To Provide Cash Runway Into The Second Quarter Of 2026
Leap Therapeutics Says Net Proceeds From April 2024 $37.2M Financing, Combined With Existing Cash, Cash Equivalents And Marketable Securities Of $54.9M, Are Expected To Provide Cash Runway Into The Second Quarter Of 2026
Leap Therapeutics表示，2024年4月3,720萬美元融資的淨收益，加上現有的現金、現金等價物和5,490萬美元的有價證券，預計將爲2026年第二季度提供現金流道
Leap Therapeutics Says Net Proceeds From April 2024 $37.2M Financing, Combined With Existing Cash, Cash Equivalents And Marketable Securities Of $54.9M, Are Expected To Provide Cash Runway Into The Second Quarter Of 2026
Leap Therapeutics表示，2024年4月3,720萬美元融資的淨收益，加上現有的現金、現金等價物和5,490萬美元的有價證券，預計將爲2026年第二季度提供現金流道
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。